| Cellular senescence: defining a path forward V Gorgoulis, PD Adams, A Alimonti, DC Bennett, O Bischof, C Bishop, ... Cell 179 (4), 813-827, 2019 | 1822 | 2019 |
| Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells G Napolitani, A Rinaldi, F Bertoni, F Sallusto, A Lanzavecchia Nature immunology 6 (8), 769-776, 2005 | 1383 | 2005 |
| Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma M Compagno, WK Lim, A Grunn, SV Nandula, M Brahmachary, Q Shen, ... Nature 459 (7247), 717-721, 2009 | 1281 | 2009 |
| Cellular senescence: aging, cancer, and injury A Calcinotto, J Kohli, E Zagato, L Pellegrini, M Demaria, A Alimonti Physiological reviews 99 (2), 1047-1078, 2019 | 836 | 2019 |
| Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation G Fabbri, S Rasi, D Rossi, V Trifonov, H Khiabanian, J Ma, A Grunn, ... Journal of Experimental Medicine 208 (7), 1389-1401, 2011 | 790 | 2011 |
| Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia D Rossi, S Rasi, V Spina, A Bruscaggin, S Monti, C Ciardullo, ... Blood, The Journal of the American Society of Hematology 121 (8), 1403-1412, 2013 | 605 | 2013 |
| Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N= 4532) M Montopoli, S Zumerle, R Vettor, M Rugge, M Zorzi, CV Catapano, ... Annals of Oncology 31 (8), 1040-1045, 2020 | 594 | 2020 |
| Pro-senescence therapy for cancer treatment C Nardella, JG Clohessy, A Alimonti, PP Pandolfi Nature Reviews Cancer 11 (7), 503-511, 2011 | 508 | 2011 |
| Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness D Rossi, A Bruscaggin, V Spina, S Rasi, H Khiabanian, M Messina, ... Blood, The Journal of the American Society of Hematology 118 (26), 6904-6908, 2011 | 490 | 2011 |
| Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma R Crescenzo, F Abate, E Lasorsa, M Gaudiano, N Chiesa, F Di Giacomo, ... Cancer cell 27 (4), 516-532, 2015 | 441 | 2015 |
| The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ... Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011 | 424 | 2011 |
| The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development D Rossi, V Trifonov, M Fangazio, A Bruscaggin, S Rasi, V Spina, S Monti, ... Journal of Experimental Medicine 209 (9), 1537-1551, 2012 | 423 | 2012 |
| BET proteins as targets for anticancer treatment A Stathis, F Bertoni Cancer discovery 8 (1), 24-36, 2018 | 418 | 2018 |
| Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity A Toso, A Revandkar, D Di Mitri, I Guccini, M Proietti, M Sarti, S Pinton, ... Cell reports 9 (1), 75-89, 2014 | 404 | 2014 |
| Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia D Rossi, M Fangazio, S Rasi, T Vaisitti, S Monti, S Cresta, S Chiaretti, ... Blood, The Journal of the American Society of Hematology 119 (12), 2854-2862, 2012 | 395 | 2012 |
| Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma DM Kurtz, F Scherer, MC Jin, J Soo, AFM Craig, MS Esfahani, JJ Chabon, ... Journal of Clinical Oncology 36 (28), 2845, 2018 | 386 | 2018 |
| Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer D Di Mitri, A Toso, JJ Chen, M Sarti, S Pinton, TR Jost, R D’Antuono, ... Nature 515 (7525), 134-137, 2014 | 358 | 2014 |
| IL-23 secreted by myeloid cells drives castration-resistant prostate cancer A Calcinotto, C Spataro, E Zagato, D Di Mitri, V Gil, M Crespo, ... Nature 559 (7714), 363-369, 2018 | 318 | 2018 |
| The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs M Boi, E Gaudio, P Bonetti, I Kwee, E Bernasconi, C Tarantelli, A Rinaldi, ... Clinical Cancer Research 21 (7), 1628-1638, 2015 | 311 | 2015 |
| PTEN level in tumor suppression: how much is too little? A Carracedo, A Alimonti, PP Pandolfi Cancer research 71 (3), 629-633, 2011 | 311 | 2011 |
